SPRB - NASDAQ
Spruce Biosciences, Inc.
$49.05
-0.22%Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
At a Glance
Live SnapshotSpruce Biosciences, Inc. Management Team
Dr. Javier Szwarcberg M.D., M.P.H.
Chief Executive Officer & Director
Compensation
$950,500
Dr. Kirk Ways M.D., Ph.D.
Chief Medical Officer & Director
Compensation
$51,750
Mr. Michael G. Grey
Executive Chairman
Compensation
$70,000
Mr. Samir M. Gharib CPA, M.B.A.
President & Chief Financial Officer
Compensation
$680,025
Spruce Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $25K worth of SPRB shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
210.0K
24.62K
0
0.00
+25K
+$25K
Top Buyers
Ways Kirk
Director, Officer: Interim Chief Medical Officer
$4K
Spiegelman Daniel K
Director
$3K
Simpson Camilla V
Director
$3K
Grey Michael G
Director, Officer: Executive Chairman
$3K
Barretto-Ko Percival
Director
$3K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $25K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
SPRB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 09, 2026 | April 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 09, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 22, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 05, 2023 | May 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 07, 2022 | May 25, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 02, 2021 | May 20, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.